The Epstein-Barr virus (EBV) is a ubiquitous human gamma-herpesvirus. It has been associated with several human malignancies, among them endemic Burkitt's lymphoma, central nervous system lymphoma in AIDS, Hodgkin's disease and nasopharyngeal carcinoma (for reviews see Kie and Liebowitz, 1990; Miller, 1990; Joske and Knecht, 1993) . In vitro, infection of primary B cells leads to outgrowth of continually proliferating cell lines (LCLs). The entire viral genome of about 170 kpb is maintained in these immortalized cells, and only a small subset of proteins is expressed including the latent membrane protein 1 (LMP1). LMP1 is expressed in atypical lymphoproliferative disorders, in the majority of nasopharyngeal carcinoma tumor cells and in Reed-Sternberg cells from Hodgkin's lymphoma, in which the only other EBV proteins detected are EBNA1 and LMP2 (FaÊ hraeus et al., 19988; Herbst et al., 1991; Pallesen et al., 1991; Knecht et al., 1995) . These observations suggest that this oncoprotein may play a determinant role in the pathogenesis of these diseases.
LMP1 is an integral membrane protein of 386 amino acids, with a short cytoplasmic N-terminal region, six transmembrane-spanning domains and a 195 amino acid long cytoplasmic C-terminal domain (Fennewald et al., 1984; Liebowitz et al., 1986) . It was shown to have oncogenic properties (Wang et al., 1985; Baichwal and Sugden, 1988) and to be essential for the transformation of B-lymphocytes in vitro (Hammerschmidt and Sugden, 1989; Kaye et al., 1993) . In B-lymphoblasts, LMP1 induces most of the phenotypic eects of EBV infection, including expression of activation markers and adhesion molecules and altered growth (Wang et al., 1988; Peng and Lungdren 1992) . In epithelial cells, LMP1 does inhibit cell differentiation (Dawson et al., 1990; FaÊ hraeus et al., 1990) . LMP1 is likely to transform cells by activating a growth receptor pathway since it has been shown to interact with human proteins related to the eectors of tumor necrosis factor receptor signalling (Mosialos et al., 1995) . It has multiple downstream eects on cell growth and gene expression, at least some of which are NF-kB mediated (HammarskoÈ ld and Simurda, 1992; Laherty et al., 1992) .
The transcription factor NF-kB was ®rst identi®ed as a DNA-binding protein speci®c for the kB motif in the immunoglobulin k light chain enhancer in Blymphocytes (for reviews see Liou and Baltimore, 1993; Grimm and Bauerle, 1993; Thanos and Maniatis, 1995; Matthews and Hay, 1995) . Subsequently it was shown to participate in the transcriptional activation of multiple growth-related genes. The NF-kB/Rel family contains various dimeric complexes composed of structurally related polypeptides, including p50 (NFkB1), p52 (NF-kB2), RelA (p65), RelB and the protooncoprotein c-Rel. The dimers are retained in the cytoplasm as inactive complexes by inhibitory molecules named IkB. The posttranslational modi®cations of IkB by phosphorylation or proteolytic cleavage, induced by various stimuli and/or viral infection causes the release of NF-kB, which then translocates to the nucleus. As NF-kB/Rel activity is tightly maintained in the cytoplasm in most cells, deregulation or imbalance among dierent members of the NF-kB/Rel and IkB families can potentially cause disorders of the immune system and of lymphoid dierentiation. Although the LMP1 oncogene is necessary for cell transformation (Wang et al., 1985; Kaye et al., 1993) , the mechanisms regulating EBV-induced oncogenesis remain poorly understood. Activation of NF-kB may be an important component of LMP1 function, since at least one of the genes induced by LMP1, ICAM-1, was shown to be expressed after stimulation of NF-kB factors (van de Stolpe et al., 1994) .
In order to determine if some lymphoproliferative disorders with LMP1 expression were associated with LMP1 variants we have isolated and characterized LMP1 from several patients. Our previous work showed that in Hodgkin's disease, B-immunoblastic and T-cell lymphomas the LMP1 gene region coding for the C-terminal domain frequently contained mutational hot spots and either a 30 bp or 69 bp deletion (Knecht et al., 1993b Klein et al., 1995) . These deletions are located in a region that has been recently shown to be important for NF-kB activation (Mitchell and Sugden, 1995; Huen et al., 1995) . This led us to test whether these deletions do aect the function of the protein. We have ampli®ed and subcloned the LMP1 gene region coding for the Cterminal domain from the selected cases listed in Figure 1 . In cases HD5, HD7 and HD8, genomic DNA extracted from fresh frozen material was ampli®ed using the primer pair A 5'-CTACAA-CAAAACTGGTGGACT-3' (position 0727 ± 747, Hudson et al., 1985) and B 5'-AAGAAGGCCAGA-GGAATGT-3' (position 2010 ± 2029) as described previously (Knecht et al., 1993a) and the product subcloned into the pGEM-T vector (PROMEGA). The 675 bp long NaeI ± SmaI (XmaI) fragments were subsequently subcloned into the corresponding sites of the expression vector pSV 2 BNFL-1 (designated as WT in this study), which encodes the LMP1 gene isolated from prototype strain B95-8 (Baichwal and Sugden, 1987, 1988) . The resulting plasmids lead to the expression of a hybrid LMP1 protein, the N-terminal and transmembrane domains being identical to the LMP1 protein from strain B95-8, and the C-terminal domain (amino acids 232 to 386) being encoded by LMP1 gene sequences isolated from patients. Another ampli®cation strategy was chosen in the case LPD, due to a higher divergence of the nucleotide sequence in the 3' untranslated region of the LMP1 gene that prevented the ampli®cation with primer B. The genomic DNA was therefore ampli®ed using the primer pair C 5'-CAACAAGCTACCGATGATTCT-3' (position 0862 ± 0882, Hudson et al., 1985) and D 5'-GGTTAGTCATAGTAGCTTAGC-3'
(position 1393 ± 1413). Cases MI, DRC and Ji were chosen as controls and ampli®ed similarly. The LMP1 gene region coding for the C-terminal domain isolated from MI, Ji, DRC, LPDa and LPDb were similarly subcloned into the expression vector pSV 2 BNFL-1. The unique SmaI restriction site of the pSV 2 BNFL-1 expression vector was ®rst transformed into a SacII site using a SacII adapter. The 480 bp NaeI ± SacII fragment (The SacII site is located in the pGEM-T polylinker) was then subcloned into the NaeI and SacII site of the adapted pSV 2 BNFL-1 vector. The resulting constructs miss 224 bp of the 3' untranslated region of the LMP1 gene, but encode a complete 386 amino acid LMP1 hybrid as above.
We have used the activation of NF-kB as an assay for LMP1 function in cells transiently transfected with the wild-type or variant LMP1 genes. Two plasmids, 3X-kB-L or 3X-mutkB-L were used as reporter. These plasmids have a minimal fos promoter and three copies of either the histocompatibility complex (MHC) class I kB element TGGGGATTCCCCA or its altered counterpart TGCGGATTCCCGA in front of the ®re¯y luciferase gene (Mitchell and Sugden, 1995) . The reporter plasmids were cotransfected with the expression vector coding for wild type or variant LMP1 (eector plasmids), either in 293 or in Rat-1 cells as shown in Figure 2 . The human embryonic kidney cell line 293 has been previously used to demonstrate NF-kB activation by LMP1 (Mitchell and Sugden, 1995) , whereas the Rat-1 rodent fibroblast cell line has been used to demonstrate the oncogenic properties of LMP1 (Wang et al., 1985) . The plasmid pCMV-p50/65 (NF-kB/relA) (Mitchell and Sugden, 1995) containing a chimeric p50/65 gene was used as a positive control. The cells were lysed 24 h after the transfection and the luciferase activity measured following standard methods. As shown in Figure 2 , wild-type LMP1 is capable of stimulating transcription from an NF-kB-responsive element promoter. LMP1 increases luciferase activity in Rat-1 ®broblasts approximately eightfold over the levels seen in non-expressing cells, and about 30-fold in the human embryonic kidney cells 293. The reporter plasmid 3X-mutkB-L containing point mutations in the NF-kB sites is not transactivated in presence of LMP1 or NF- Knecht et al., 1995; LPD, Klein et al., 1995) . MI is derived from cord blood lymphocytes infected with serum from a patient with infectious mononucleosis. Ji (Jijoye) is an EBV positive Burkitt's lymphoma cell line. DRC is a benign tumor of dendritic reticulum cells. HD5 is an initial lymph node biopsy of a patient with Hodgkin's disease in remission after one relapse. HD7 is an initial lymph node biopsy of therapy resistant Hodgkin's disease. HD8 is an initial lymph node biopsy of a patient with Hodgkin's disease that had relapses after 2 and 5 years. LPD is a juvenile EBV-associated lymphoproliferative syndrome; LPDa is a lymph node biopsy and LPDb a lung biopsy. The location of the deletions are indicated by arrows. bp: base pairs; aa: amino acids kB/relA (Figure 2) , indicating that the transactivation is speci®c in both cell lines. We further used the human 293 cell line to test LMP1 variants since this cell line gave a higher NF-kB-mediated stimulation. We observed a mean decrease of about 70% of the activity with mutant CD55 that lacks amino acids 331 to 386 (Figure 3 ), in agreement with previously published results (Michell and Sugden, 1995; Huen et al., 1995) . In contrast, the LMP1 30 bp deletion variants HD5, HD7, and HD8 did stimulate NF-kB to the same level as the wild-type form (Figure 3) . These results indicate that the deletion of 10 amino acids, located between amino acids 345 and 355 does not aect NF-kB activation. Concentration-dependent experiments con®rmed that the amount plasmids coding for wild-type or mutant LMP1 used in the system was saturating. A similar decrease in luciferase activity is observed when diluting either the eector plasmid encoding wild-type or the deletion variants, with a 50% stimulation reached at about 0.2 mg eector plasmid (data not shown). A similar level of activity is reached with variants WT/LPDa and WT/ LPDb, characterized by a 23 amino acid deletion located between residues 332 to 354. This variant is of special interest since this deletion does overlap the CD55 truncation (see Figure 1) . Therefore we analysed the NF-kB dependent ICAM-1 upregulation for the 30 and 69 base pair deletion variants and the construct CD55 by immunohistochemical identi®cation of ICAM-1 protein on cytospins. The assays were performed as described (Knecht et al., 1996) . In two to ®ve independent transfection experiments there was no decrease in the number and speci®c staining intensity of ICAM-1 expressing 293 cells with the HD5 and LPD variants when compared to WT. However, the carboxy terminal truncation variant CD55 showed nearly no ICAM-1 induction; only occasional single cells showed a weak immunostaining for ICAM-1. To measure LMP1 expression we have performed Western blots of WT, HD5 and LPD, and compared them to the number of cells identi®ed by immunostaining on cytospins. By immunostaining an equal amount of 293 cells was strongly positive for oncoprotein expression when transfected with either Figure 2 Stimulation of NF-kB reporter activity by wild-type LMP1 in transfected Rat1 (A) or 293 (B) cells. Cells were transfected with 2 mg of each plasmid using Lipofectin (Gibco BRL). Activation of NF-kB was determined by measuring the activity of the luciferase enzyme produced from cotransfected reporter plasmid 3X-kB-L or 3X-mutkB-L. All luciferase data were corrected for the protein content of each sample and were expressed as relative light units (RLU)/mg protein extract. The mean+s.d. was calculated from three separate experiments WT, HD5 or LPD. Speci®c bands of expected length were identi®ed in protein extracts from WT, HD5 and LPD. Equal strength of bands was seen in WT and HD5, whereas LPD showed a less intense band not correlating with the number of positive cells identi®ed on the cytospins. This dierence is probably related to a loss of speci®c antibody epitopes located within the 23 amino acids deleted in the LPD variant.
These ®ndings indicate that crucial residues for maximal NF-kB stimulation of transcription are contained within the last 32 amino acids of the Cterminal domain of the LMP1 oncogene. These residues may be important for interactions with some cellular components, either alone or more probably in combination with other parts of the LMP1 protein since their absence signi®cantly reduces but not abolishes NF-kB stimulation, as shown with CD55.
An important implication of our results is that all the naturally occurring variants tested in our study have fully retained their capabilities of stimulating NFkB-mediated transcription, although they have point mutations and/or deletions in the C-terminal domain. This demonstrates that NF-kB activation is an important feature of LMP1 function and that the critical residues for this function remain conserved during evolution. Recent studies by us and others suggest that such deletion variants, while maintaining the NF-kB activation, also display an enhanced oncogenic activity (Knecht et al., 1996; Li et al., 1996) .
